Description Anti-oxLDL is a novel full length human IgG1 antibody that selectively targets a specific atherogenic epitope on oxidized LDL (oxLDL). Preclinical studies suggest that there is a strong link between oxLDL and the inflammatory processes that leads to unstable plaque formation in vessel walls. Plaque rupture leads to heart attack and stroke.

Development Status A Phase II clinical trial evaluating Anti-oxLDL for secondary prevention of cardiac events was completed in the second quarter of 2009. Nexts steps are under evaluation.

This molecule is being developed in collaboration with BioInvent.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

October 2009